<DOC>
	<DOCNO>NCT00887289</DOCNO>
	<brief_summary>The main goal open-label , prospective , non-controlled , non-interventional post marketing surveillance study evaluate pramipexole treatment work apply actual practice . In actual practice patient would exclude clinical registration study pramipexole moderate severe primary Restless Legs Syndrome ( i.e . certain disease history , co-morbidities and/or demographic characteristic ) also treat pramipexole . Thus , post marketing surveillance study additional information efficacy safety pramipexole patient obtain . The objective post marketing surveillance study : - To investigate influence Sifrol® ( pramipexole ) treatment unpleasant sensory symptom Restless Legs Syndrome measure short form McGill Pain Questionnaire . - To assess improvement sensory symptom correlate overall Restless Legs Syndrome severity ( International Restless Legs Syndrome Scale Severity ) secondary symptom like sleep problem daytime tiredness ( item 1 &amp; 6 Restless Legs Syndrome-6 ) . - To evaluate treatment effect Sifrol overall Restless Legs Syndrome severity ( International Restless Legs Syndrome Scale Severity ) differ patient high pain score patient low pain score . - To compare General Practitioner neurologist sit patient population term demographic , Restless Legs Syndrome severity Visit 1 treatment outcome Visit 3 . - To evaluate development behavioural change pramipexole treatment .</brief_summary>
	<brief_title>Non-interventional Observational Study Influence Pramipexole Sensory Symptoms Restless Legs Syndrome ( RLS )</brief_title>
	<detailed_description>Study Design :</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis primary moderate severe Restless Legs Syndrome . 2 . Patients plan treat Sifrol® ( pramipexole ) decision treatment make independent patient ' inclusion post marketing surveillance study . 3 . Male female patient age least 18 year . 4 . Written informed consent patient study participation . Exclusion criterion : 1 . Any contraindication accord Summary Product Characteristics : hypersensitivity pramipexole excipients . 2 . Previous ongoing treatment Sifrol® ( pramipexole ) . 3 . Previous ongoing treatment dopamine receptor agonist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>